Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Eniola Odetunde/Axios

STAT News is planning a big expansion next year, thanks in part to explosive growth during the COVID-19 pandemic.

The big picture: The health, medicine and science outlet brought in over $10 million in revenue this year — up about 66% from last year, executives tell Axios. It plans to increase staff by roughly 40% next year to help launch new data products, events and custom reports.

STAT was one of the first U.S. outlets to begin seriously covering the pandemic in January. It went from roughly 1.5 million monthly uniques prior to the pandemic to 23 million in March.

  • Traffic is now at a steady 6 million monthly uniques over the past few months, which STAT co-founder and executive editor Rick Berke anticipates will be the site's "new normal."
  • "We were poised for by far our most successful year, but covid propelled us a lot faster,' Berke says, noting that the company plans to expand its coverage to Europe next year.

Between the lines: STAT was also one of the first outlets in the U.S. to drop its paywall for COVID-19 coverage. The boom in traffic prompted the company to begin accepting donations.

  • Berke says the company has received "tens of thousands" in donations this year, a surprising standalone revenue stream for the company.
  • The company has quickly become one of the most trusted news sources amid the pandemic. That includes STAT’s Helen Branswell, a top infectious disease reporter.
  • "These are stories you can't just throw at a reporter and expect them to understand," says Berke.

STAT's explosive growth has caught the attention of advertisers, even though it makes most of its money selling subscriptions to its paywalled news product STAT+. While most companies are reeling from advertiser losses, STAT says it's seen a huge uptick in its ads businesses, as well as events.

  • Total ad deal volume increased 33% year-over-year. Event revenue overall in 2019 was more than $1 million and grew 30% this year.
  • The company is planning to add a third virtual summit to its events lineup next year, focused on breakthrough science in July, per STAT's Chief Revenue Officer Angus Macaulay. Sponsorships for the events are mostly sold out, Berke says.

It's also planning to launch two new products catered to high-end users. The first, which will likely be accessible to subscribers, is a data service that would allow subscribers to sort through complicated data sets, like clinical trials data.

  • The second is to expand its series of deep-dive reports into topics like remote patient monitoring and Chinese biotech that are sold for hundreds of dollars to individuals, or via a group license.

STAT's mission is to cover complicated topics in a way that's both sexy and relatable. Prior to the launch of STAT, most high-end coverage of those topics was found in medical journals.

  • The company is in talks to license the rights to its 80-minute documentary film about a double-amputee and MIT scientist who creates brain-controlled robotic limbs. It's closing in on a deal with a linear TV network. That deal, if brokered, would also allow STAT to sell the film to a streamer.

Flashback: STAT owners John Henry and Linda Pizzuti Henry funded the creation of STAT in 2015 after the pair purchased The Boston Globe and a few other smaller properties from New York Times in 2013 for $70 million.

  • In an interview, Pizzuti Henry, who was named CEO of the Globe this month, said STAT helps to diversify their portfolio of mostly Boston-based outlets.
  • "Having a mix of audiences that we can appeal to is important," she said, recognizing that the pandemic has been a boon to STAT, but tougher on local media.

Niche media outlets have found some success in the past few years, targeting small but loyal audiences and charging them for high-end content.

  • "We don't pretend to be biggest, but we like to think that every day we have stories no one else has about health and medicine that are authoritative and provocative and rigorous and ambitious," Berke said.

What's next: Pizzuti Henry says that she and her husband, who are also principal owners of the Boston Red Sox, have no plans to sell STAT, and that they are doing research now to invest in other new niche media startups.

Go deeper

Jan 29, 2021 - Health

J&J says its one-shot vaccine is 66% effective against moderate to severe COVID

Photo: Thiago Prudêncio/SOPA Images/LightRocket via Getty Images

Johnson & Johnson announced Friday that its single-shot coronavirus vaccine was 66% effective in protecting against moderate to severe COVID-19 disease in Phase 3 trials, which was comprised of nearly 44,000 participants across eight countries.

Between the lines: The vaccine was 72% effective in the U.S., but only 57% effective in South Africa, where a more contagious variant has been spreading. It prevented 85% of severe infections and 100% of hospitalizations and deaths, according to the company.

Jan 30, 2021 - World

Science helps New Zealand avoid another coronavirus lockdown

New Zealand Prime Minister Jacinda Ardern (L) visits a lab at Auckland University in December. Photo: Phil Walter/Getty Images

New Zealand has avoided locking down for a second time over COVID-19 community cases because of a swift, science-led response.

Why it matters: The Health Ministry said in an email to Axios Friday there's "no evidence of community transmission" despite three people testing positive after leaving managed hotel isolation. That means Kiwis can continue to visit bars, restaurants and events as much of the world remains on lockdown.

Jan 29, 2021 - Health

Ex-CDC director Tom Frieden on the next COVID-19 vaccines

Americans fortunate enough to receive COVID vaccines now, outside of clinical trials, are getting shots made by either Pfizer or Moderna. But newly released data from Novavax and Johnson & Johnson suggests that more vaccines could be on the way, with J&J's requiring a single dose.

Axios Re:Cap digs into the news and why it matters with Tom Frieden, former head of the CDC, as COVID-19 variants spread globally.